Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)
Ratios

Agios Pharmaceuticals (AGIO) Accumulated Depreciation & Amortization: 2012-2024

  • Agios Pharmaceuticals' Accumulated Depreciation & Amortization rose 8.17% to $56.5 million in Q4 2024 from the same period last year, while for Dec 2024 it was $203.8 million, marking a year-over-year increase of 8.03%. This contributed to the annual value of $56.5 million for FY2024, which is 8.17% up from last year.
  • Latest data reveals that Agios Pharmaceuticals reported Accumulated Depreciation & Amortization of $56.5 million as of Q4 2024, which was up 8.17% from $52.2 million recorded in Q4 2023.
  • Agios Pharmaceuticals' Accumulated Depreciation & Amortization's 5-year high stood at $56.5 million during Q4 2024, with a 5-year trough of $41.4 million in Q4 2020.
  • In the last 3 years, Agios Pharmaceuticals' Accumulated Depreciation & Amortization had a median value of $52.2 million in 2023 and averaged $52.9 million.
  • Data for Agios Pharmaceuticals' Accumulated Depreciation & Amortization shows a peak YoY climbed of 28.78% (in 2020) over the last 5 years.
  • Agios Pharmaceuticals' Accumulated Depreciation & Amortization (Quarterly) stood at $41.4 million in 2020, then increased by 8.76% to $45.0 million in 2021, then grew by 11.33% to $50.1 million in 2022, then rose by 4.31% to $52.2 million in 2023, then increased by 8.17% to $56.5 million in 2024.
  • Its Accumulated Depreciation & Amortization stands at $56.5 million for Q4 2024, versus $52.2 million for Q4 2023 and $50.1 million for Q4 2022.